PAR-20-314 - Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Trials Not Allowed) is used for the submission of applications to the following Notices of Special Interest (NOSIs)
On This Page: 1
Active NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|---|---|---|---|---|
Notice of Special Interest (NOSI): Utilization of Cohorts and Prospective Study Designs for Liquid Biopsy Assay Validation for Early Detection of Cancers | NOT-CA-23-004 | NCI | Oct 17, 2022 | Jul 2, 2025 | R43/R44, R21, R01, UH2/UH3, R41/R42, U01 |
Expired NOSIs
Title | Notice Number | Organization | Release Date |
Expiration Date |
Activity Code(s) |
---|